Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr El-Jawahri on the Impact of Palliative Care on End-of-Life Care for AML and MDS

August 12th 2024

Areej El-Jawahri, MD, discusses a trial investigating a palliative oncology care model for patients with AML and MDS receiving nonintensive therapy.

Dr Grunwald on a Real-World Study of Risk Factors For Disease Progression in PV

August 9th 2024

Michael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.

AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

August 7th 2024

Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.

AYA ALL: Pediatric and Adult Inspired Regimens

August 7th 2024

Focusing on the current treatment landscape for patients with AYA ALL, the panel discusses clinical practices and treatment decisions based on age.

Dr Hernandez-Ilizaliturri on CAR T-Cell Therapy vs Bispecific Antibodies in DLBCL

August 6th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses deciding between CAR T-cell therapies or approved bispecific antibodies for diffuse large B-cell lymphoma.

Outpatient Treatment With Subcutaneous Epcoritamab Shows Feasibility in R/R DLBCL and Follicular Lymphoma

August 5th 2024

Subcutaneous epcoritamab demonstrated safety when given in the outpatient setting in relapsed/refractory diffuse large B-cell and follicular lymphoma.

FDA Requests Additional Demonstration of OS Benefit to Support Iomab-B BLA in R/R AML

August 5th 2024

The FDA is requiring an additional trial demonstrating an OS benefit with Iomab-B to support the planned filing of the biologics license application for the agent.

Alemtuzumab Earns FDA Orphan Drug Designation for Lymphodepletion Before UCART22 in R/R B-ALL

August 2nd 2024

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Munir on Cost and QOL Outcomes With Zanubrutinib vs Acalabrutinib in B-Cell Malignancies

August 2nd 2024

Talha Munir, MBChB, PhD, discusses an adverse effect–based economic analysis of zanubrutinib vs acalabrutinib in patients with B-cell malignancies.

Dr Rijneveld on the Addition of Blinatumomab to Prephase and Consolidation Therapy in B-ALL

August 1st 2024

Anita Rijneveld, MD, discusses outcomes with the addition of blinatumomab to prephase and consolidation therapy for patients with adult B-cell acute lymphoblastic leukemia.

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

August 1st 2024

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Dr Platzbecker on First-Line ATRA/ATO in High-Risk Acute Promyelocytic Leukemia

July 31st 2024

Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.

AYA ALL: Overview and Risk Stratification

July 31st 2024

Experts on acute lymphoblastic leukemia share their clinical experiences, describe high-risk features, and provide insights on risk stratification practices.

Clinical Scenario: A 23-Year-Old Male with AYA ALL

July 31st 2024

A panel of experts from Atrium Health Levine Cancer Institute present a patient case and provide an overview of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL).

Asciminib Receives FDA Priority Review for Newly Diagnosed Ph+ CP-CML

July 30th 2024

The FDA has granted priority review to asciminib for newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Dr Pollyea on the Mechanism of Revumenib in KMT2A-Rearranged R/R AML

July 30th 2024

Dan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.

FDA Extends PDUFA Date for Revumenib in KMT2A-Rearranged Acute Leukemia

July 29th 2024

The FDA has extended the PDUFA date for the NDA seeking the approval of revumenib for patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

July 24th 2024

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Dr Watts on the Investigation of INCB057643 in Advanced Myelofibrosis and MPN

July 24th 2024

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia

July 23rd 2024

Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.